Successful treatment of Gaucher disease type 1 by enzyme replacement therapy over a 10-year duration in a Japanese pediatric patient: A case report

Oto,Yuji; Inoue,Takeshi; Nagai,So; Tanaka,Shinichiro; Itabashi,Hisashi; Shiraisihi,Masahisa; Nitta,Akihisa; Murakami,Nobuyuki; Ida,Hiroyuki; Matsubara,Tomoyo

doi:10.3892/etm.2021.9677

Successful treatment of Gaucher disease type 1 by enzyme replacement therapy over a 10-year duration in a Japanese pediatric patient: A case report

Authors:
- Yuji Oto
- Takeshi Inoue
- So Nagai
- Shinichiro Tanaka
- Hisashi Itabashi
- Masahisa Shiraisihi
- Akihisa Nitta
- Nobuyuki Murakami
- Hiroyuki Ida
- Tomoyo Matsubara
View Affiliations

Affiliations: Department of Pediatrics, Saitama Medical Center, Dokkyo Medical University, Koshigaya, Saitama 343-8555, Japan, Department of Pediatrics, The Jikei University School of Medicine, Tokyo 105-8471, Japan
Published online on: January 22, 2021 https://doi.org/10.3892/etm.2021.9677
Article Number: 246

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prevalence of Gaucher disease (GD) in Japan is much lower than that in Western countries; therefore, data on Japanese pediatric patients with GD type 1 are currently limited. The present study reports on the case of a Japanese pediatric patient with GD type 1 who was diagnosed when she presented with hepatosplenomegaly, thrombocytopenia and slight anemia at the age of 2 years. Serology tests revealed high levels of acid phosphatase (ACP) and angiotensin‑converting enzyme (ACE). A bone marrow biopsy revealed the presence of Gaucher cells. Abdominal MRI indicated huge hepatosplenomegaly. Erlenmeyer flask deformity was observed on X‑ray examination. MRI of the femora featured a high‑intensity area within the diaphysis region. The enzymatic activity of leukocyte β‑glucosidase, the measurement of which is necessary for a definitive diagnosis of GD, had decreased to 186.7 nmol/h/mg (reference range, 1,424.0‑2,338.0 nmol/h/mg). Based on these results, the patient was clinically diagnosed with GD. Glucocerebrosidase gene analysis identified the compound heterozygote mutation of F213I (c.754T>A) on exon 7 and L444P (c.1448T>C) on exon 11. Enzyme replacement therapy (ERT) along with an intravenous infusion of 60 U/kg of imiglucerase every other week was initiated following diagnosis. Hemoglobin levels and the platelet count gradually improved and normalized after two years. ACP and ACE levels, biomarkers of the progression of GD, also improved. Abdominal MRI at six months after the initiation of ERT revealed a decrease in the size of the liver and spleen, which normalized after 1 year. Conversely, MRI of the femora indicated no improvement in the high‑intensity area within the diaphysis region for 10 years.

View Figures

View References

1	Baris HN, Cohen IJ and Mistry PK: Gaucher disease: The metabolic defect, pathophysiology, phenotypes and natural history. Pediatr Endocrinol Rev. 12 (Suppl 1):72–81. 2014.PubMed/NCBI
2	Cox TM and Schofield JP: Gaucher's disease: Clinical features and natural history. Baillieres Clin Haematol. 10:657–689. 1997.PubMed/NCBI View Article : Google Scholar
3	Thomas AS, Mehta A and Hughes DA: Gaucher disease: Haematological presentations and complications. Br J Haematol. 165:427–440. 2014.PubMed/NCBI View Article : Google Scholar
4	Hruska KS, La Marca ME, Scott CR and Sidransky E: Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 29:567–583. 2008.PubMed/NCBI View Article : Google Scholar
5	Eto Y, Ida H, Ohashi T, Okuyama T, Sakai N, Takayanagi M, Narita A and Nanba E (eds): Gaucher Disease Update. 1st edition. Shindantochiryousha, pp91-92, 2016 (In Japanese).
6	Starzyk K, Richards S, Yee J, Smith SE and Kingma W: The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab. 90:157–163. 2007.PubMed/NCBI View Article : Google Scholar
7	Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE and van Diggelen OP: The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 105:151–156. 1999.PubMed/NCBI View Article : Google Scholar
8	Tajima A, Yokoi T, Ariga M, Ito T, Kaneshiro E, Eto Y and Ida H: Clinical and genetic study of Japanese patients with type 3 Gaucher disease. Mol Genet Metab. 97:272–277. 2009.PubMed/NCBI View Article : Google Scholar
9	Ida H, Rennert OM, Kawame H, Maekawa K and Eto Y: Mutation prevalence among 47 unrelated Japanese patients with Gaucher disease: Identification of four novel mutations. J Inherit Metab Dis. 20:67–73. 1997.PubMed/NCBI View Article : Google Scholar
10	Andersson H, Kaplan P, Kacena K and Yee J: Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics. 122:1182–1190. 2008.PubMed/NCBI View Article : Google Scholar
11	Boot RG, Verhoek M, de Fost M, Hollak CE, Maas M, Bleijlevens B, van Breemen MJ, van Meurs M, Boven LA, Laman JD, et al: Marked elevation of the chemokine CCL18/PARC in Gaucher disease: A novel surrogate marker for assessing therapeutic intervention. Blood. 103:33–39. 2004.PubMed/NCBI View Article : Google Scholar
12	Hollak CE, van Weely S, van Oers MH and Aerts JM: Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest. 93:1288–1292. 1994.PubMed/NCBI View Article : Google Scholar
13	Arkadir D, Dinur T, Revel-Vilk S, Becker Cohen M, Cozma C, Hovakimyan M, Eichler S, Rolfs A and Zimran A: Glucosylsphingosine is a reliable response biomarker in Gaucher disease. Am J Hematol. 93:E140–E142. 2018.PubMed/NCBI View Article : Google Scholar
14	Ida H, Rennert OM, Kobayashi M and Eto Y: Effects of enzyme replacement therapy in thirteen Japanese paediatric patients with Gaucher disease. Eur J Pediatr. 160:21–25. 2001.PubMed/NCBI View Article : Google Scholar
15	Grabowski GA, Kacena K, Cole JA, Hollak CE, Zhang L, Yee J, Mistry PK, Zimran A, Charrow J and vom Dahl S: Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet Med. 11:92–100. 2009.PubMed/NCBI View Article : Google Scholar
16	Wenstrup RJ, Roca-Espiau M, Weinreb NJ and Bembi B: Skeletal aspects of Gaucher disease: A review. Br J Radiol. 75 (Suppl 1):A2–A12. 2002.PubMed/NCBI View Article : Google Scholar
17	Mendelsohn E, Meir A, Abrahamov A, Elstein D, Zimran A and Levy-Khademi F: Growth and final height of children with Gaucher disease: A 15-year follow-up at an Israeli Gaucher center. Blood Cells Mol Dis. 68:97–99. 2018.PubMed/NCBI View Article : Google Scholar
18	Robertson PL, Maas M and Goldblatt J: Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher's disease using the bone marrow burden score. AJR Am J Roentgenol. 188:1521–1528. 2007.PubMed/NCBI View Article : Google Scholar
19	Vom Dahl S, Poll L, Di Rocco M, Ciana G, Denes C, Mariani G and Maas M: Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. Curr Med Res Opin. 22:1045–1064. 2006.PubMed/NCBI View Article : Google Scholar
20	Hughes D, Mikosch P, Belmatoug N, Carubbi F, Cox T, Goker-Alpan O, Kindmark A, Mistry P, Poll L, Weinreb N, et al: Gaucher Disease in Bone: From Pathophysiology to Practice. J Bone Miner Res. 34:996–1013. 2019.PubMed/NCBI View Article : Google Scholar
21	Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, vom Dahl S and Hollak C: Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis. 36:543–553. 2013.PubMed/NCBI View Article : Google Scholar
22	Charrow J, Dulisse B, Grabowski GA and Weinreb NJ: The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet. 71:205–211. 2007.PubMed/NCBI View Article : Google Scholar
23	Sims KB, Pastores GM, Weinreb NJ, Barranger J, Rosenbloom BE, Packman S, Kaplan P, Mankin H, Xavier R, Angell J, et al: Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: Results of a 48-month longitudinal cohort study. Clin Genet. 73:430–440. 2008.PubMed/NCBI View Article : Google Scholar
24	Poll LW, Koch JA, vom Dahl S, Willers R, Scherer A, Boerner D, Niederau C, Häussinger D and Mödder U: Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: First German long-term results. Skeletal Radiol. 30:496–503. 2001.PubMed/NCBI View Article : Google Scholar
25	Poll LW, Maas M, Terk MR, Roca-Espiau M, Bembi B, Ciana G and Weinreb NJ: Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol. 75 (Suppl 1):A25–A36. 2002.PubMed/NCBI View Article : Google Scholar
26	Simonaro CM, Haskins ME and Schuchman EH: Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: A possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest. 81:1319–1328. 2001.PubMed/NCBI View Article : Google Scholar
27	Horowitz M, Tzuri G, Eyal N, Berebi A, Kolodny EH, Brady RO, Barton NW, Abrahamov A and Zimran A: Prevalence of nine mutations among Jewish and non-Jewish Gaucher disease patients. Am J Hum Genet. 53:921–930. 1993.PubMed/NCBI
28	Beutler E, Gelbart T and West C: Identification of six new Gaucher disease mutations. Genomics. 15:203–205. 1993.PubMed/NCBI View Article : Google Scholar
29	Ida H, Rennert OM, Ito T, Maekawa K and Eto Y: Type 1 Gaucher disease: Phenotypic expression and natural history in Japanese patients. Blood Cells Mol Dis. 24:73–81. 1998.PubMed/NCBI View Article : Google Scholar
30	Ida H, Owen MR, Iwasawa K, Kobayashi M and Eto Y: Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation. J Hum Genet. 105:120–126. 1999.PubMed/NCBI View Article : Google Scholar